Alpha Tau Medical Ltd (DRTS)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Operating profit | $m | -42 | -50 | ||||||
| Net profit | $m | -9 | -27 | -34 | -29 | -32 | -43 | -93 | -77 |
| EPS reported | $ | -0.53 | -1.04 | ||||||
| Operating cashflow per share | $ | -0.33 | -0.29 | ||||||
| Capex per share | $ | 0.08 | 0.07 | ||||||
| FCF per share | $ | -0.41 | -0.36 | ||||||
| Free cash flow | $m | -33 | -33 | ||||||
| Net debt | $m | -71 | -94 | ||||||
| Book value equity | $m | 77 | 44 | ||||||
| Book value per share | $ | 0.96 | 0.48 | ||||||
| Number of shares | m | 80.58 | 90.95 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 5.17 | 9.05 | ||||||
| P/S LTM | x | 0.00 | 0.00 | ||||||
| P/FCF LTM | x | -12.18 | -12.18 | ||||||
| EV/EBITDA LTM | x | -9.66 | -8.08 | ||||||
| EV/Sales LTM | x | 0.00 | 0.00 | ||||||
| Earnings Yield LTM | % | -10.69% | -7.14% | ||||||
| FCF Yield | % | -8.21% | -8.21% | ||||||
| Quality | |||||||||
| ROE | % | -55.29% | -138.12% | ||||||
| ROIC | % | -43.50% | -40.04% | ||||||
| Operating margin | % | 0.00% | 0.00% | ||||||
| Gross margin | % | 0.00% | 0.00% | ||||||
| FCF/Sales | % | - | - | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | - | - | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -2.39 | -2.16 | ||||||
| Net Debt/EBITDA | x | 0.05 | 0.16 | ||||||
| EBIT/Net interest | x | -100.93 | -1.15 | ||||||
| Net debt/market cap | % | +1.59% | +0.53% | ||||||
| Net debt/Equity | x | -0.92 | -2.13 | ||||||
| Gross debt/equity | x | 0.18 | 0.34 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors. The company is headquartered in Jerusalem, Israel.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors. The company is headquartered in Jerusalem, Israel.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free